PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Prostate Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Hoag Memorial Hospital Presbyterian, Irvine, California, United States
Contact: Study coordinator (Beth Thomsen) · beth.thomsen@hoag.org
Contact: Principal Investigator (Gary Ulaner, MD)

Study leads

Deborah Fridman, PsyD, RN
Study Director
Hoag Memorial Hospital Presbyterian

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

Abroad (travel likely)RecruitingPHASE1, PHASE2

Los Angeles, United States · El Paso, United States

A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer

Prostate Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Wuhan, China

Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Fuzhou, China

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

Prostate Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Chengdu, China · Tianjin, China